Your browser doesn't support javascript.
loading
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Grassl, Niklas; Sahm, Katharina; Süße, Heike; Poschke, Isabel; Bunse, Lukas; Bunse, Theresa; Boschert, Tamara; Mildenberger, Iris; Rupp, Anne-Kathleen; Ewinger, Max Philipp; Lanz, Lisa-Marie; Denk, Monika; Tabatabai, Ghazaleh; Ronellenfitsch, Michael W; Herrlinger, Ulrich; Glas, Martin; Krex, Dietmar; Vajkoczy, Peter; Wick, Antje; Harting, Inga; Sahm, Felix; von Deimling, Andreas; Bendszus, Martin; Wick, Wolfgang; Platten, Michael.
Afiliação
  • Grassl N; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.
  • Sahm K; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany.
  • Süße H; DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.
  • Poschke I; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.
  • Bunse L; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany.
  • Bunse T; DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.
  • Boschert T; National Center for Tumor Diseases (NCT) Trial Center, NCT, Heidelberg, Germany.
  • Mildenberger I; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.
  • Rupp AK; Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Ewinger MP; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.
  • Lanz LM; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany.
  • Denk M; DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.
  • Tabatabai G; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.
  • Ronellenfitsch MW; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany.
  • Herrlinger U; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.
  • Glas M; DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.
  • Krex D; Helmholtz Institute for Translational Oncology (HI-TRON), Mainz, Germany.
  • Vajkoczy P; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Wick A; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.
  • Harting I; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany.
  • Sahm F; DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.
  • von Deimling A; National Center for Tumor Diseases (NCT) Trial Center, NCT, Heidelberg, Germany.
  • Bendszus M; National Center for Tumor Diseases (NCT) Trial Center, NCT, Heidelberg, Germany.
  • Wick W; National Center for Tumor Diseases (NCT) Trial Center, NCT, Heidelberg, Germany.
  • Platten M; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
Neurol Res Pract ; 5(1): 55, 2023 Oct 19.
Article em En | MEDLINE | ID: mdl-37853454
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article